Cyclooxygenase (COX)-2 as a potent molecular target for prevention and therapy of oral cancer

Japanese Dental Science Review

Volumn 44, Issue 1, 2008, Pages 57-65

  Urade, Masahiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Carcinogenesis; Cyclooxygenase (COX) 2; Malignant phenotype; Oral cancer; Therapeutic target

Indexed keywords

EID: 53549134434     PISSN: 18827616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdsr.2007.10.003     Document Type: Review

References (86)

1. Pindborg J.J. Atlas of diseases of the oral mucosa. 5th ed. (1992), WB Saunders, Philadelphia
2. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics 2004. CA Cancer J Clin 54 (2004) 8-29
3. Von Dongen G.A., and Snow G.B. Prospectives for future studies in head and neck cancer. Eur J Surg Oncol 23 (2007) 485-491
4. Regezi J.A., Sciubba J.J., and Jordan R.C. Oral pathology. 4th ed. (2003), WB Saunders, St. Louis p. 52-71
5. Forastiere A., Koch W., and Trotti A. Medical progress: head and neck cancer. N Engl J Med 345 (2001) 1890-1900
6. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
7. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., and Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55 (1995) 2556-2559
8. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55 (1995) 3785-3789
9. Ristimaki A., Honkanen N., Jankala H., Sipponen P., and Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57 (1997) 1276-1280
10. Parrett M.L., Harris R., Joarder F.S., Ross M.S., Clausen K.P., and Robertson F.M. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10 (1997) 503-507
11. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancer, specifically in adenocarcinomas. Cancer Res 58 (1998) 3761-3764
12. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., and Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59 (1999) 198-204
13. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
14. Shirahama T., and Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res 7 (2001) 558-561
15. Yoshimura R., Sano H., Masuda C., Kawamura M., Tsubouchi Y., Chargui J., et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 (2000) 589-596
16. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 (1999) 991-994
17. Sakurai K., Urade M., Noguchi K., Kishimoto H., Ishibashi M., Yasoshima H., et al. Increased expression of cyclooxygenase-2 in human salivary gland tumors. Pathol Int 51 (2001) 762-769
18. Peng J., Su C., Chang H.C., Chai C.Y., and Hung W.C. Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma of the hypopharynx. Hum Pathol 33 (2002) 100-104
19. Smith W.L., Garavito R.M., and De Witt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
20. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83 (1995) 493-501
21. Huang M., Stolina M., Sharma S., Mao J.T., Zhu L., Miller P.W., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin-10 and down-regulation of interleukin-12 production. Cancer Res 58 (1998) 1208-1216
22. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
23. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94 (1997) 3336-3340
24. Leong J., Hughes-Fulford M., Rakhlin N., Habib A., MacLouf J., and Goldyne M.E. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 224 (1996) 79-87
25. Thun M.J., Namboodiri M.M., and Heath C.W.J. Aspirin use and reduced colon cancer. N Engl J Med 325 (1991) 1593-1596
26. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333 (1995) 609-614
27. Smalley W., and DuBois R.N. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 39 (1995) 1-20
28. Scully C., Field J.K., and Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN). 1. Carcinogen metabolism DNA repair and cell cycle control. Oral Oncol 36 (2000) 256-263
29. Scully C., Field J.K., and Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma. 2. Chromosomal aberrations. Oral Oncol 36 (2000) 311-327
30. Scully C., Field J.K., and Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma. 3. Clinico-pathological applications. Oral Oncol 36 (2000) 404-413
31. Shibata M., Kodani I., Osaki M., Araki K., Adachi H., Ryoke K., et al. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 41 (2005) 304-312
32. Segawa E, Sakurai K, Kishimoto H, Takaoka K, Noguchi K, Hashitani S, et al. Expression of cyclooxygenase-2 and DNA topoisomarase IIα in precancerous and cancerous lesions of the oral mucosa. Oral Oncol; 2007 Nov 8 [Epub ahead of print].
33. Renkonen J., Wolff H., and Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch 440 (2002) 594-597
34. Sudbo J., Ristimaki A., Sondresen J.E., Kildal W., Boysen M., Koppang H.S., et al. Cyclo-oxygenase-2 (COX-2) in high-risk premalignant oral lesions. Oral Oncol 39 (2003) 497-505
35. Ratnasinghe D., Tangrea J., Roth M.J., Dawsey S., Hu N., Anver M., et al. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey. Anticancer Res 19A (1999) 171-174
36. Ranelletti F.O., Almadori G., Rocca B., Ferrandina G., Ciabattoni G., Habib A., et al. Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95 (2001) 343-349
37. Nozoe T., Ezaki T., Kabashima A., Baba H., and Maehara Y. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 189 (2005) 110-115
38. Kuroda J., Urade M., Kishimoto H., Noguchi K., Hashitani S., Sakurai K., et al. Promotion of cell differentiation, and suppression of cell growth and cyclooxygenase-2 expression by differentiation-inducing agents in human oral squamous carcinoma SCC25 cells. Int J Oncol 26 (2005) 361-367
39. Sheehan K.M., Sheahan K., O'Donoghue D.P., MacSweeney F., Conroy R.M., Fitzgerald D.J., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282 (1999) 1254-1257
40. Tomozawa S., Tsuno N.H., Sunami E., Hatano K., Kitayama J., Osada T., et al. Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83 (2000) 324-328
41. Masunaga R., Kohno H., Dhar D.K., Ohno S., Shibakita M., Kinugasa S., et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6 (2000) 4064-4068
42. Konno H., Baba M., Shoji T., Ohta M., Suzuki S., and Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metast 19 (2002) 527-534
43. Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., and Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33 (2002) 708-714
44. Chang B.W., Kim D.H., Kowalski D.P., Burleson J.A., Son Y.H., Wilson L.D., et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 10 (2004) 1678-1684
45. Joo Y.E., Kim H.S., Min S.W., Lee W.S., Park C.S., Choi S.K., et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Cancer 31 (2002) 147-154
46. Peterson S., Haroske G., Hellmich G., Ludwig K., Peterson C., and Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 22 (2002) 1225-1230
47. Zhang H., and Sun X.F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastoenterol 97 (2002) 1037-1041
48. Fux R., Schwab M., Thon K.-P., Gleiter C.H., and Fritz P. Cyclooxygenase-2 in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 11 (2005) 4754-4760
49. Sakurai K., Urade M., Noguchi K., Hashitani S., Takaoka K., Segawa E., et al. Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIα expressions in oral carcinoma. Head Neck 29 (2007) 1002-1009
50. 2 production. J Oral Pathol Med 30 (2001) 41-47
51. Toyoshima T., Kamijo R., Takizawa K., Sumitani K., Ito D., and Nagumo M. Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer 86 (2002) 1150-1156
52. Kinugasa Y., Hatori M., Ito H., Kurihara Y., and Nagumo M. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metast 21 (2004) 737-745
53. Hashitani S., Urade M., Nishimura N., Maeda T., Takaoka K., Noguchi K., et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective COX-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 23 (2003) 665-672
54. Takaoka K., Kishimoto H., Segawa E., Hashitani S., Zushi Y., Noguchi K., et al. Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol 29 (2006) 1095-1101
55. Yamazaki D., Kurisu S., and Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 96 (2005) 379-386
56. Boolbol S.K., Dannenberg A.J., Chadburn A., Martucci C., Guo X.J., Ramonetti J.T., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by slindac in a murine model of familial polyposis. Cancer Res 56 (1996) 2556-2560
57. Rao C.V., Rivenson A., Simi B., Zang E., Kelloff G., Steele V., et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55 (1995) 1464-1472
58. Reddy B.S., Rao C.V., and Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56 (1996) 4566-4569
59. Giardiello F.M., Offerhaus G.J.A., and DuBois R.N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 31A (1995) 1071-1076
60. Δ716 knockout mice by inhibition of prostaglandin endoperoxide syntheses-2 (COX-2). Cell 87 (1996) 803-809
61. Williams C.S., Smalley W., and DuBois R.N. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100 (1997) 1-5
62. Shiotani H., Denda A., Yamamoto K., Kitayama W., Endoh T., Sasaki Y., et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, numesulide. Cancer Res 61 (2001) 1451-1456
63. Yamamoto K., Kitayama W., Denda A., Morisaki A., Kuniyasu H., and Kirita T. Inhibitory effects of selective cyclooxygenase-2 inhibitors, nimesulide and etodolac, on the development of squamous cell dysplasias and carcinomas of the tongue in the rats initiated with 4-nitioquinoline 1-oxide. Cancer Lett 199 (2003) 121-129
64. Yoshida K., Tanaka T., Kohno H., Sakata K., Kawamori T., Mori H., et al. A COX-2 inhibitor, nimesulide, inhibits chemically induced rat tongue carcinogenesis through suppression of cell proliferation activity and COX-2 and iNOS expression. Histol Histopathol 18 (2003) 39-48
65. Nishimura N., Urade M., Hashitani S., Noguchi K., Manno Y., Takaoka K., et al. Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 33 (2004) 614-621
66. Nishimura G., Yanoma S., Mizuno H., Kawakami K., and Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mice xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90 (1999) 1152-1162
67. Liao Z., Mason K.A., and Milas L. Cyclo-oxygenase-2 and its inhibition in cancer. Drugs 67 (2007) 821-845
68. Amirghahari N., Harrison L., Smith M., Romg X., Naumann I., Ampil F., et al. NS398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2. Int J Radiat Oncol Biol Phys 57 (2003) 1405-1412
69. Raju U., Ariga H., Dittmann K., Nakata E., Ang K.K., and Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys 63 (2005) 520-528
70. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
71. Milas L., Furuta Y., Hunter N., Nishiguchi I., and Runkel S. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immnocompetence. Cancer Res 50 (1990) 4473-4477
72. Liao Z., Komaki R., Milas L., Yuan C., Kies M., Chang J.Y., et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11 (2005) 3342-3348
73. Hida T., Leyton J., Makheja A., Ben-Av P., Hla T., Martinez A., et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res 18 (1998) 775-782
74. Duffy C.P., Elliot C.J., O'Connor R.A., Heenan M.M., Coyle S., Cleary M., et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34 (1998) 1250-1259
75. Hida T., Kozaki K., Ito H., Miyaishi O., Tatematsu Y., Suzuki T., et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8 (2002) 2443-2447
76. Nakata E., Mason K., Hunter N., Husain A., Raju U., Liao Z., et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 inhibitors. Int J Radiat Oncol Biol Phys 58 (2004) 369-375
77. Altorki N.K., Keresztes R.S., Port J.L., Libby D.M., Korst R.J., Flieder D.B., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer. J Clin Oncol 21 (2003) 2645-2650
78. Shin D.M., Ro J.Y., Hong W.K., and Hittelman W.N. Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis. Cancer Res 54 (1994) 3153-3159
79. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
80. Chen Z., Zhang X., Li M., Wang Z., Wieand H.S., Grandis J.R., et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10 (2004) 5930-5939
81. Zhang X., Chen Z., Choe M.S., Lin Y., Sun S.Y., Wieand H.S., et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11 (2005) 6261-6269
82. Milas L., Mason K., Hunter N., Petersen S., Yamakawa M., Ang K., et al. In vivo enhancement of tumor redioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6 (2000) 323-325
83. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., and DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23 (2005) 254-266
84. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
85. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
86. White W.B., Faich G., Whelton A., Maurath C., Ridge N.J., Verburg K.M., et al. Comparison of thromboemboric events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89 (2002) 425-430